Swiss National Bank
ARQT icon

Swiss National Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Swiss National Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
224,000
+5,800
+3% +$135K ﹤0.01% 1352
2026
Q1 		$5.14M Buy
218,200
+5,400
+3% +$138K ﹤0.01% 1358
2025
Q4 		$6.18M Buy
212,800
+4,900
+2% +$125K ﹤0.01% 1238
2025
Q3 		$3.92M Buy
207,900
+3,900
+2% +$61.5K ﹤0.01% 1458
2025
Q2 		$2.86M Hold
204,000
– – ﹤0.01% 1597
2025
Q1 		$3.19M Sell
204,000
-2,900
-1% -$40.9K ﹤0.01% 1510
2024
Q4 		$2.88M Buy
206,900
+3,300
+2% +$36.2K ﹤0.01% 1648
2024
Q3 		$1.89M Hold
203,600
– – ﹤0.01% 1900
2024
Q2 		$1.89M Buy
+203,600
New +$1.84M ﹤0.01% 1847
2023
Q4 		– Sell
-101,200
Closed -$537K – 2542
2023
Q3 		$537K Buy
101,200
+9,100
+10% +$77.4K ﹤0.01% 2496
2023
Q2 		$878K Hold
92,100
– – ﹤0.01% 2362
2023
Q1 		$1.01M Sell
92,100
-9,600
-9% -$139K ﹤0.01% 2244
2022
Q4 		$1.51M Buy
101,700
+3,900
+4% +$68.1K ﹤0.01% 2073
2022
Q3 		$1.87M Buy
97,800
+26,600
+37% +$603K ﹤0.01% 1916
2022
Q2 		$1.52M Buy
71,200
+11,700
+20% +$240K ﹤0.01% 2109
2022
Q1 		$1.15M Buy
59,500
+4,300
+8% +$72.7K ﹤0.01% 2341
2021
Q4 		$1.15M Hold
55,200
– – ﹤0.01% 2398
2021
Q3 		$1.32M Hold
55,200
– – ﹤0.01% 2294
2021
Q2 		$1.51M Sell
55,200
-1,000
-2% -$28.2K ﹤0.01% 2277
2021
Q1 		$1.63M Buy
56,200
+31,900
+131% +$996K ﹤0.01% 2126
2020
Q4 		$684K Buy
24,300
+3,000
+14% +$73.5K ﹤0.01% 2417
2020
Q3 		$624K Hold
21,300
– – ﹤0.01% 2304
2020
Q2 		$644K Buy
+21,300
New +$616K ﹤0.01% 2309

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Swiss National Bank's ARQT Position: Q2 2026 in Review

Swiss National Bank increased its Arcutis Biotherapeutics (ARQT) stake by 2.7% in Q2 2026, buying an estimated $135K and bringing the position to 224,000 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Swiss National Bank first reported a position in ARQT in Q2 2020 and has held it in 23 quarters since. The position peaked at $6.18M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Swiss National Bank held 224,000 shares of Arcutis Biotherapeutics worth $5.87M as of Q2 2026.
  • Swiss National Bank bought 5,800 Arcutis Biotherapeutics shares in Q2 2026, an estimated $135K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1352 holding.
  • Swiss National Bank first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 23 quarters since.
  • Swiss National Bank's Arcutis Biotherapeutics position peaked at $6.18M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.